Rather good news for TEVA's future
Eli Lilly's Cymbalta goes generic in December. Sales of Cymbalta by Lilly are expected to fall from about $5B to $1.5B about 70% drop in sales. Lilly's Evista will go generic in March 2014, with Teva being one of two companies holding 180 days of exclusivity in the U.S. Lilly's sales estimated at about $400M, a drop of about 50%. All these facts seem to predict a bleak outlook for Lilly and an important addition to the bright future of Teva.
MNTA presented its plans at the Credit Suisse Healthcare Conference and I find it very informative. It seems that 2014 will be an important year in MNTA's work and drugs development. In particular
if MNTA will be successful in creating a higher standard of structural characterization and fingerprint like similarity between MNTA's product and the branded products, there is a strong possibility that there may be reduced clinical requirement associated with MNTA's products
Eli Lilly's Cymbalta goes generic in December. Sales of Cymbalta by Lilly are expected to fall from about $5B to $1.5B about 70% drop in sales. MNTA is going to catch a piece of the action (unfortunately, others too, including TEVA) . This seem to predict a bleak outlook for Lilly and an important addition to the bright future of MNTA.
and any comments about this:
In 2009 TEVA's CEO Shlomo Yanai reduced the investment in R&D from about 19% to about 6% of sales
This number did not change significantly since then and it is about 7 % of sales now.
Is this information correct ? (the source of the graph mentioned below is from Morningstar)
Does anybody know what was Yanai's rational in making this cut which has an important impact on TEVA's future ?
Did Levine intend to change this number before he left ?
See the graph in
I tend to agree with redshington_washskins2 and his comment about Yanai's possible motives